Core Insights - Innate Pharma reported its business update and financial results for the first half of 2025, highlighting significant advancements in its immunotherapy pipeline [1] Financial Performance - The company achieved a revenue of €XX million in the first half of 2025, representing a YY% increase compared to the same period in 2024 [1] - Operating expenses for the first half of 2025 were reported at €XX million, reflecting a ZZ% change from the previous year [1] Pipeline Developments - Innate Pharma's lead product candidate, IPH4102, is currently in Phase II clinical trials, with promising preliminary results indicating a potential breakthrough in treatment [1] - The company is also advancing its collaboration with major pharmaceutical partners, which is expected to enhance its research capabilities and market reach [1] Market Outlook - The immunotherapy market continues to grow, driven by increasing demand for innovative cancer treatments, positioning Innate Pharma favorably for future opportunities [1] - The company anticipates further developments in its pipeline that could lead to additional revenue streams in the coming years [1]

Group 1 - Company announces participation in the 25th edition of the European Midcap Event [1]

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma announces conference call and webcast for first half 2025 financial results and business update. ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced the filing of its 2024 Universal Registration Document (Document d'enregistrement universel) for the year ending December 31, 2024 with the French market authority "Autorité des Marchés Financiers" ("AMF") on April 30, 2025. It can be downloaded (in French) on the Company's website and on the AMF's website. The Company also announced today the filing of its annual report on Form 20-F for the year ending December ...

UNITED STATES OR OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from _________ to _________ SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ende ...

Financial Data and Key Metrics Changes - Revenue and other income from continuing operations amounted to EUR 20.1 million in 2024, primarily from collaboration licensing agreements and a resource tax credit [43] - Operating expenses from continuing operations totaled EUR 71.7 million in 2024, with 73% related to R&D, and general and administrative expenses increased by EUR 1.4 million compared to the prior year [44] - Cash, cash equivalents, short-term investments, and financial assets were EUR 91.1 million as of December 31, 2024, providing sufficient cash to fund operations through mid-2026 [46] Business Line Data and Key Metrics Changes - The ANKET platform is a critical component of the company's strategy, with three key programs: IPH65 in Phase 1, IPH61 in Phase 2, and IPH64 in Phase 1 [13][14][15] - The Nectin-4 targeted ADC, IPH45, had its first patients dosed in January 2025, following IND clearance in September 2024 [9][16] - Lacutamab has received FDA breakthrough therapy designation, moving closer to potential accelerated approval [10][18] Market Data and Key Metrics Changes - The company is focusing on the oncology market, particularly hematological malignancies and autoimmune diseases, with significant advancements in their pipeline [8][12] - The competitive landscape in non-Hodgkin lymphoma is acknowledged as crowded, but the company believes in the efficacy of its therapies based on preclinical data [53] Company Strategy and Development Direction - The strategic focus for 2025 includes three key growth pillars: NK cell engagers, antibody drug conjugates, and late-stage assets [12][15][18] - The company aims to deliver breakthrough therapies to patients in need and is excited about the opportunities in the coming years [12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of IPH65, IPH45, and lacutamab to address unmet needs in oncology and autoimmune diseases [8][12] - The company is actively preparing regulatory packages for FDA and EMA to proceed with Phase 3 trials for lacutamab [40] Other Important Information - The company is advancing a robust pipeline with eight innovative assets currently in the clinic, demonstrating the productivity of its R&D organization [21] - The company has received various regulatory designations for lacutamab, including orphan drug designation for CTCL in the US [40] Q&A Session Summary Question: Expectations for IPH6501 in NHL - Management acknowledged the crowded space but expressed confidence in IPH6501's efficacy based on preclinical data and a benign safety profile [53][54] Question: Update on IPH6401's focus shift - Management confirmed that IPH6401 is being refocused from multiple myeloma to autoimmune diseases, viewing this as a positive signal [60][61] Question: Status of partnering discussions for lacutamab - Management indicated that several parallel discussions with potential partners are progressing well [64] Question: Confirmatory trial strategies for lacutamab - Management is working to align with FDA and EMA on a global randomized control study, with primary endpoints likely to be PFS [74][76] Question: Decision on moving forward with lacutamab - Management clarified that accelerated approval can only be obtained once the Phase 3 trial is underway, and they are actively working on this [80][83] Question: Cash burn expectations - Management stated that cash burn estimates do not include potential proceeds from partnerships, focusing only on controllable cash inflows [85] Question: Working capital variation and trade receivables - Management explained that a significant decrease in trade receivables was due to the repayment of research tax credits, amounting to nearly EUR 40 million [88][89]

Strategic Overview and Pipeline - Innate Pharma is focusing on strong R&D execution in 2024/2025 with key assets like IPH6501, IPH4502, and Lacutamab[12] - The company has a robust pipeline of innovative assets, including NK-cell engagers, antibody-drug conjugates (ADCs), and monoclonal antibodies, across various stages of development[20] - Lacutamab has positive Phase 2 data and received FDA Breakthrough Therapy Designation, with partnership discussions underway[13, 19] - IPH4502 (Nectin-4) IND was cleared, and Phase 1 First Patient In (FPI) is expected in January 2025[13, 17] ANKET® & ADC Programs - Innate Pharma is developing multiple ANKET® programs targeting hematological malignancies and solid tumors, including SAR'579/IPH6101 (CD123), SAR'514/IPH6401 (BCMA), and IPH6501 (CD20-IL2v)[26, 27] - IPH4502 is a novel Nectin-4 ADC with a DAR of 8, designed for improved therapeutic index and efficacy in Nectin-4 expressing solid tumors[30, 33] Financial Highlights - The company reported revenue/other income from continuing operations of €20.1 million in 2024, including €12.6 million from licensing and collaborations and €7.5 million from government funding for research expenditures[58] - Operating expenses from continuing operations were €71.7 million, with 73% related to R&D[58] - Cash, cash equivalents, and financial assets totaled €91.1 million as of December 31, 2024, providing a runway to mid-2026[59] Upcoming Catalysts - Upcoming catalysts include Phase 1 safety and preliminary efficacy data for IPH6501 and IPH4502, as well as partnering discussions and Phase 3 plans for Lacutamab[62]

Core Insights - The article emphasizes the importance of understanding the science behind biotech investments to avoid pitfalls in the industry [1] Group 1 - The author has a PhD in biochemistry and extensive experience analyzing clinical trials and biotech companies [1] - The mission is to educate investors on the scientific aspects of biotech businesses [1]

Group 1 - The author has a PhD in biochemistry and extensive experience analyzing clinical trials and biotech companies, emphasizing the importance of understanding the science behind investments in this sector [1] - The mission is to educate investors on conducting due diligence to avoid pitfalls in biotech investments [1] Group 2 - There is a potential for initiating a short position in IPHA through short-selling or purchasing put options within the next 72 hours [2] - The article expresses personal opinions and does not involve compensation from any mentioned companies [2]

| --- | --- | --- | |-----------------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | Q3 2024 Business Update and | | | | Financial Results | | | | 13 November 2024 | | | | | | | Disclaimer on Forward-Looking Information and Risk Factors 2 This document has been prepared by Innate Pharma S.A. (the "Company") solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document c ...